Eli Lilly & Co. - LLY STOCK NEWS

The EMPA-KIDNEY trial, assessing Jardiance (empagliflozin) for chronic kidney disease (CKD), is set to stop early due to positive efficacy results from the Independent Data Monitoring Committee. This trial, the largest of its kind in CKD, involves over 6,600 participants with various kidney function levels. The primary goal is to evaluate kidney disease progression and cardiovascular death. The trial's findings aim to address significant unmet medical needs in CKD, a global health crisis affecting millions. Detailed results will be presented later this year.

Eli Lilly and Company (NYSE: LLY) will present data on pirtobrutinib and Verzenio at the 2022 American Association for Cancer Research (AACR) Annual Meeting from April 8-13, 2022. Key presentations include the BRUIN Phase 1b study results on pirtobrutinib for chronic lymphocytic leukemia and data on Verzenio’s efficacy against CDK4/6i resistance in breast cancer. These findings will enhance understanding of treatment options and potential outcomes for patients with relapsed conditions. Posters will be accessible on-demand until July 13, 2022.

Eli Lilly and Company (NYSE: LLY) is set to participate in the Barclays Global Healthcare Conference on March 15, 2022. Patrik Jonsson, senior vice president and president of Lilly Immunology, will engage in a fireside chat at 10:15 a.m. ET. Investors and the public can access a live audio webcast through Lilly's Investor website. A replay will be available for approximately 90 days. Lilly continues its commitment as a global healthcare leader, dedicated to discovering life-changing medicines.

Eli Lilly and Boehringer Ingelheim announced that Jardiance (empagliflozin) demonstrated a 36% higher clinical benefit in adults hospitalized for acute heart failure in the EMPULSE phase III trial, compared to placebo. The study, comprising 530 patients, evaluated composite endpoints including mortality and frequency of heart failure events. Jardiance also improved quality of life as measured by the Kansas City Cardiomyopathy Questionnaire. The FDA has previously approved Jardiance for reducing cardiovascular death risk in heart failure patients, contributing to its third approval related to the EMPOWER program.

Eli Lilly and Company (NYSE: LLY) will participate in the Cowen Health Care Conference on March 8, 2022. Anat Ashkenazi, Lilly's CFO, will engage in a virtual fireside chat at 10:30 a.m. Eastern Time. A live audio webcast will be accessible on Lilly's Investor website, with a replay available for 90 days. Lilly is dedicated to creating high-quality medicines and enhancing community well-being through philanthropy. For more details, visit www.lilly.com.

The FDA has approved Jardiance (empagliflozin) 10 mg for reducing the risk of cardiovascular death and hospitalization for heart failure in adults. This marks a significant advancement for nearly 3 million U.S. adults with heart failure with preserved ejection fraction, expanding treatment options in a sector with limited alternatives. Jardiance previously received approval for heart failure with reduced left ventricular ejection fraction. The approval is based on the EMPEROR-Preserved phase III trial, which showed a 21% risk reduction in cardiovascular events.

Eli Lilly and Company (NYSE: LLY) has launched the Lilly Institute for Genetic Medicine with a $700 million investment to establish a new facility in Boston Seaport. This initiative aims to advance RNA-based therapeutics, leveraging existing expertise from its 2020 acquisition of Prevail Therapeutics. The Boston site plans to grow its team from 120 to over 250 specialists over the next five years. Additionally, the facility will support biotech start-ups, potentially creating 150 new jobs. The Institute is expected to enhance research in neurodegenerative diseases.

In the pivotal LUCENT-1 Phase 3 study, Eli Lilly's mirikizumab demonstrated statistically superior clinical remission rates at 12 weeks in patients with moderately-to-severely active ulcerative colitis, achieving 24.2% versus 13.3% for placebo (p=0.00006). Key secondary endpoints also showed significant improvements, with 63.5% of patients responding to treatment. Mirikizumab's safety profile was consistent with previous studies, reporting lower serious adverse events (2.8% vs. 5.3% for placebo). Lilly plans to submit a Biologics License Application to the FDA in early 2022.

Eli Lilly and Company (NYSE: LLY) has launched a new education campaign aimed at raising awareness of breast cancer recurrence risks. Collaborating with organizations like Breastcancer.org and Living Beyond Breast Cancer, the initiative focuses on individuals diagnosed with hormone receptor-positive, HER2-negative early breast cancer. With over 290,000 expected diagnoses in the U.S. in 2022, the campaign provides resources to help patients understand individual risk factors for recurrence. Educational materials include a digital fact sheet and patient conversation guide.